Orchestra BioMed (OBIO) CEO David Hochman Buys 10,000 Shares

What Happened
David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed (OBIO), reported an open-market purchase of 10,000 shares on 2026-09-03. The weighted-average price reported was $4.79, for an aggregate reported value of $47,900. The filing describes the transaction as a purchase (code P), indicating an insider buy rather than a sale.

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-08 (see note on timeliness below).
• Price: weighted-average $4.79; purchases occurred at prices ranging $4.73–$4.79 (footnote).
• Shares acquired: 10,000; total reported value: $47,900.
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote: the $4.79 price is a weighted average across multiple trades; the reporting person offers to provide a breakout of the number of shares at each price on request.
• Timeliness: filing date is 2026-09-08 for a 2026-09-03 trade. The provided data does not include a timeliness flag; Form 4s are typically due within two business days of the transaction—review the full filing for any late-filing disclosure.

Context

• This was a direct purchase by the CEO/Chair rather than an option exercise, award, or gift. Insider purchases are often scanned by investors for potential confidence signals, but they are not definitive proof of future performance.
• No indication in the excerpt that shares were immediately sold (cashless exercise) or that the trade was part of a pre-arranged plan (e.g., Rule 10b5‑1).